Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
September 16, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Novel T-Cell Immunotherapies Market, 2030
September 10, 2021 05:58 ET
|
Research and Markets
Dublin, Sept. 10, 2021 (GLOBE NEWSWIRE) -- The "Novel T-Cell Immunotherapies Market: Focus on T-Cells, Tregs, Activated T-Cells, Virus-driven T-Cells & T-Cell Vaccines - Distribution by Type of...
CRISPR Based Therapeutics Market, 2030
September 09, 2021 08:43 ET
|
Research and Markets
Dublin, Sept. 09, 2021 (GLOBE NEWSWIRE) -- The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global...
Global Oligonucleotide Synthesis Market Report 2021: Market is Poised for Explosive Growth as Gene Technology Moves into Mainstream Healthcare, Food Production and, Even, Data Storage
August 03, 2021 06:58 ET
|
Research and Markets
Dublin, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team
July 20, 2021 08:00 ET
|
Arbor Biotechnologies Inc
- Pam Stetkiewicz, Ph.D., Appointed Chief Operating Officer - Kathryn McCabe, Ph.D., Named SVP, Head of Business Development CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Arbor...
Global Gene Therapy Market 2021-2027 - COVID-19 Causes Gene Therapy Market to Buckle & Collapse
July 13, 2021 03:28 ET
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global market for Gene Therapy...
Global $34.31 Billion Cell and Gene Therapy Markets, 2015-2020, 2025F, 2030F
July 12, 2021 04:38 ET
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
Global Cell Therapy Market Report 2021 Featuring Fibrocell Science., JCR Pharma, PHARMICELL, Osiris, MEDIPOST, Vericel, Anterogen, Kolon TissueGene, Stemedica Cell Technologies, and AlloCure
June 30, 2021 04:33 ET
|
Research and Markets
Dublin, June 30, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global cell...
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
June 26, 2021 11:15 ET
|
Intellia Therapeutics, Inc.
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean...